Pediatric Hematology / Oncology Research
The Division of Pediatric Hematology and Oncology at Hasbro Children’s Hospital offers a wide array of clinical trials that bring the most advanced cancer and blood disorder treatments to the children of Rhode Island and neighboring Massachusetts and Connecticut. We believe that offering cutting-edge medical therapies to patients close to home is of utmost importance. In addition, we are advancing medical science by participating in numerous biology and scientific studies that will one day lead to a cure for childhood cancer and blood diseases.
Hasbro Children’s Hospital is a full member of the Children's Oncology Group as well as the Dana-Farber Acute Lymphoblastic Leukemia Consortium. In addition, we are founding members of both the Consortium for New England Childhood Cancer Survivors and the New England Pediatric Sickle Cell Consortium. Through these national and regional groups, we have novel therapies and new treatment protocols available for virtually every pediatric cancer patient, as well as for children dealing with chronic hematologic diseases or the long-term consequences of cancer treatment.
Rishi Lulla, MD, MS and Bradley DeNardo, MD offer world class, research-driven medicine and clinical trials, delivered to patients diagnosed with pediatric cancer and blood disorders.
Children's Oncology Group
Hasbro Children’s Hospital is one of more than 200 leading children’s hospitals and cancer centers that is a member of the Children’s Oncology Group (COG). COG is a National Cancer Institute supported group that develops clinical trials for the treatment of nearly all types of childhood cancer. The active clinical trials offered through COG and available at Hasbro Children’s Hospital include front-line treatment for many types of childhood cancers, and trials for patients with relapsed cancer involving new and emerging treatments, including immunotherapy.
Dana Farber ALL Consortium
The DFCI ALL Consortium is an international collaborative group of pediatric and adult cancer centers, led by Dana-Farber Cancer Institute, that specializes in the treatment and study of acute lymphoblastic leukemia (ALL). ALL is the most common type of cancer diagnosed in children. With our most current treatment approaches, newly diagnosed ALL is one of the most curable cancers of childhood. The DFCI ALL Consortium has performed a series of clinical trials for children with ALL since its inception in 1981. Through these trials we have witnessed a significant improvement in our ability to cure ALL. Hasbro Children’s Hospital has been an active member of the DFCI/ALL Consortium since 2007. Through our collaborative work and membership in the consortium we remain at the forefront of treatment for pediatric ALL and are able to offer our newly diagnosed ALL patients the most current clinical trials and therapies for this disease.
Go With The Flow Yoga Study
Hasbro Children’s Hospital is conducting a research study to understand more about how yoga can impact quality of life for survivors of childhood, adolescent, and young adult cancer, as well as their siblings. Participants must be between the ages of 10- and 21-years-old. E-mail email@example.com for more information.
Active Research Studies
Below is a list of all active research studies for which the Division of Pediatric Hematology and Oncology at Hasbro Children’s Hospital is currently enrolling participants.
For more information about these studies and how to participate, please contact us at 401-444-4673. For general information about clinical trials please visit the National Cancer Institute. For more information about each study, click a link below to visit that study's webpage.
Leukemia and Lymphoma
AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND# 73789, NSC# 606869) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
ANHL1131 - Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B- AL: Evaluation of Rituximab (IND #10385) Efficacy and Safety in High Risk Patients
ANHL 12P1 A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710) or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND #117117
Pediatric Brain Tumors/Neuro-Oncology
ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 yearsAEWS1221, Randomized Phase III Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Neuroblastoma and Pediatric Sarcomas
ARST1321- Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Liver Tumors, Kidney Tumors and Germ Cell Tumors
Late Effects and Epidemiology
Lifespan 1023816: Hasbro Children’s Hospital Study of Changes in Gut Microbiome in Pediatric Acute Lymphoblastic Leukemia Survivors